Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Yusuf Henriques
AddedMar 31, 2024
UpdatedMay 31, 2026
Yusuf Henriques

Yusuf Henriques

Board Member, IndyGeneUS AI

CrunchbaseLinkedIn

Yusuf Henriques's Career

IndyGeneUS AI
IndyGeneUS AI

Washington, D.C., DC, US

Board Member· Board
Polaris Genomics
Polaris Genomics

Gaithersburg, MD, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Yusuf Henriques's Career

IndyGeneUS AI
IndyGeneUS AI
Pre-Seed$1.8M62021Washington, D.C., DC, US
Board Member· Board

Leadership at IndyGeneUS AI

Bradford WilsonBradford WilsonCo-Founder

Similar to IndyGeneUS AI

Data Driven BioscienceData Driven BioscienceDurham, NC, USGenomic Toolsest. 2018Data Driven BioscienceDurham, NC, US · est. 2018

Data-driven biotech firm providing genomic tools for cancer diagnosis and treatment in clinical labs.

Seed · $120k30
BioinfoexpertsBioinfoexpertsThibodaux, LA, USGenomic Sequencingest. 2012BioinfoexpertsThibodaux, LA, US · est. 2012

BioInfoExperts: Comprehensive genomic sequencing and data analytics for infectious disease surveillance.

Pre-Seed · $1.2M10
GenomeNextGenomeNextColumbus, OH, USGenomic Analysisest. 2014GenomeNextColumbus, OH, US · est. 2014

GenomeNext offers real-time, automated genomic analysis software for researchers and clinicians.

Seed · $1.2M2
Polaris Genomics
Polaris Genomics
Pre-Seed$4.7M352017Gaithersburg, MD, US
Co-Founder

Leadership at Polaris Genomics

Hans CobbenHans CobbenBoard Member
Charles CathlinCharles CathlinCo-Founder
Tshaka CunninghamTshaka CunninghamCo-Founder

Similar to Polaris Genomics

GenomindGenomindKing of Prussia, PA, USBiomarker Testsest. 2009GenomindKing of Prussia, PA, US · est. 2009

Genomind LLC: A US-based personalized medicine firm specializing in saliva-based neuropsychiatric biomarker tests.

Series B · $74M1k
Genome MedicalGenome MedicalSouth San Francisco, CA, USGenetic Counseling, Telehealthest. 2016Genome MedicalSouth San Francisco, CA, US · est. 2016

Genome Medical: A telegenomics tech firm providing access to genomic-based medicine services.

Series C · $120.4M172
Base5 GenomicsBase5 GenomicsMountain View, CA, USGenomics, Sequencingest. 2018Base5 GenomicsMountain View, CA, US · est. 2018

Base5 Genomics: Providing sequencing solutions for personalized care and genomic diversity.

Series A · $5.3M12

Yusuf Henriques's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Yusuf Henriques

Manish GuptaManish GuptaCEO · IndegeneEric DahlhauserEric DahlhauserBoard Member · Insight GeneticsSri KosarajuSri KosarajuBoard Member · NevroWalker LongWalker LongCEO · GeneBiologyLuna YuLuna YuFounder · Genecis Bio